Acadia Pharmaceuticals Tops $1 Billion in Revenue Amid NUPLAZID Growth and IRA Rebate Adjustments
Event summary
- Acadia Pharmaceuticals reported $1.07 billion in GAAP total revenues for 2025, surpassing the $1 billion mark for the first time.
- NUPLAZID net product sales reached $680 million in 2025, with a 9% volume growth driven by underlying demand.
- DAYBUE generated $391 million in net product sales for the year, marking a 12% increase from 2024.
- The company recorded a $20 million change in estimate related to Inflation Reduction Act rebate accruals for NUPLAZID, impacting reported sales.
- Acadia expects top-line results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis between August and October 2026.
The big picture
Acadia Pharmaceuticals' strong financial performance in 2025 highlights its growing commercial footprint in neurological and rare disease treatments. The company's ability to navigate Inflation Reduction Act rebates while expanding its sales teams and product offerings will be critical as it competes with larger pharmaceutical players. The upcoming Phase 2 results for remlifanserin could further solidify Acadia’s position in the Alzheimer’s disease psychosis market.
What we're watching
- Commercial Momentum
- Whether Acadia can sustain the 13% quarterly volume growth of NUPLAZID amid Inflation Reduction Act rebate adjustments.
- Pipeline Catalysts
- The pace at which remlifanserin advances through Phase 2 trials and its potential impact on Acadia’s valuation.
- Market Expansion
- How the launch of DAYBUE STIX in early Q2 2026 will affect DAYBUE’s market penetration and revenue growth.
Related topics